NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
15:10
Four employees of the Giurgiu Penitentiary have been suspended for abusive behavior after they beat a prisoner who went into cardiac arrest.
14:59
Dominic Fritz, the mayor of Timișoara, has been fined 10% of his salary for the next 6 months.
14:51
The Deputy Governor of the BNR explains why Fitch has reconfirmed Romania's sovereign rating.
14:40
President Nicușor Dan has promulgated the law regarding the declaration of a state of crisis in the oil market and has extended the deadline for reduced VAT on housing.
14:39
The White House will host a meeting with representatives of artificial intelligence companies to analyze a framework for testing cybersecurity.
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
